Ayodeji Awoyemi

  • Senior Cardiologist; MD, PhD
  • +4722119100
 

Publications 2024

Nendl A, Andersen GØ, Seljeflot I, Trøseid M, Awoyemi A (2024)
Intestinal fatty acid binding protein is associated with infarct size and cardiac function in acute heart failure following myocardial infarction
Open Heart, 11 (2)
DOI 10.1136/openhrt-2024-002868, PubMed 39277188

Raju SC, Molinaro A, Awoyemi A, Jørgensen SF, Braadland PR, Nendl A, Seljeflot I, Ueland PM, McCann A, Aukrust P, Vestad B, Mayerhofer C, Broch K, Gullestad L, Lappegård KT, Halvorsen B, Kristiansen K, Hov JR, Trøseid M (2024)
Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity
Genome Med, 16 (1), 27
DOI 10.1186/s13073-024-01296-6, PubMed 38331891

Publications 2023

Nendl A, Raju SC, Broch K, Mayerhofer CCK, Holm K, Halvorsen B, Lappegård KT, Moscavitch S, Hov JR, Seljeflot I, Trøseid M, Awoyemi A (2023)
Intestinal fatty acid binding protein is associated with cardiac function and gut dysbiosis in chronic heart failure
Front Cardiovasc Med, 10, 1160030
DOI 10.3389/fcvm.2023.1160030, PubMed 37332580

Publications 2022

Awoyemi A, Hov JR, Trøseid M (2022)
Phenylacetylglutamine From the Gut Microbiota: A Future Therapeutic Target in Heart Failure?
Circ Heart Fail, 16 (1), e010222
DOI 10.1161/CIRCHEARTFAILURE.122.010222, PubMed 36524473

Publications 2021

Aune SK, Byrkjeland R, Solheim S, Arnesen H, Trøseid M, Awoyemi A, Seljeflot I, Helseth R (2021)
Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training
Diabetol Metab Syndr, 13 (1), 36
DOI 10.1186/s13098-021-00655-2, PubMed 33794977

Aune SK, Cwikiel J, Flaa A, Arnesen H, Solheim S, Awoyemi A, Trøseid M, Seljeflot I, Helseth R (2021)
Gut Leakage Markers in Response to Strenuous Exercise in Patients with Suspected Coronary Artery Disease
Cells, 10 (9)
DOI 10.3390/cells10092193, PubMed 34571843

Awoyemi A, Mayerhofer C, Felix AS, Hov JR, Moscavitch SD, Lappegård KT, Hovland A, Halvorsen S, Halvorsen B, Gregersen I, Svardal A, Berge RK, Hansen SH, Götz A, Holm K, Aukrust P, Åkra S, Seljeflot I, Solheim S, Lorenzo A, Gullestad L, Trøseid M, Broch K (2021)
Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial
EBioMedicine, 70, 103511
DOI 10.1016/j.ebiom.2021.103511, PubMed 34329947

Publications 2020

Mayerhofer CCK, Kummen M, Holm K, Broch K, Awoyemi A, Vestad B, Storm-Larsen C, Seljeflot I, Ueland T, Bohov P, Berge RK, Svardal A, Gullestad L, Yndestad A, Aukrust P, Hov JR, Trøseid M (2020)
Low fibre intake is associated with gut microbiota alterations in chronic heart failure
ESC Heart Fail, 7 (2), 456-466
DOI 10.1002/ehf2.12596, PubMed 31978943

Publications 2019

Awoyemi A, Trøseid M, Arnesen H, Solheim S, Seljeflot I (2019)
Effects of dietary intervention and n-3 PUFA supplementation on markers of gut-related inflammation and their association with cardiovascular events in a high-risk population
Atherosclerosis, 286, 53-59
DOI 10.1016/j.atherosclerosis.2019.05.004, PubMed 31100620

Mayerhofer CCK, Awoyemi A, Hov JR, Trøseid M, Broch K (2019)
Reply: Potential risk associated with direct modulation of the gut flora in patients with heart failure
ESC Heart Fail, 6 (3), 557-558
DOI 10.1002/ehf2.12437, PubMed 31034162

Publications 2018

Awoyemi A, Trøseid M, Arnesen H, Solheim S, Seljeflot I (2018)
Markers of metabolic endotoxemia as related to metabolic syndrome in an elderly male population at high cardiovascular risk: a cross-sectional study
Diabetol Metab Syndr, 10, 59
DOI 10.1186/s13098-018-0360-3, PubMed 30038669

Kummen M, Mayerhofer CCK, Vestad B, Broch K, Awoyemi A, Storm-Larsen C, Ueland T, Yndestad A, Hov JR, Trøseid M (2018)
Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts
J Am Coll Cardiol, 71 (10), 1184-1186
DOI 10.1016/j.jacc.2017.12.057, PubMed 29519360

Page visits: 4735